Preliminary In-vitro Study of 223Ra Impact on Selected Tissue and Tumor Cell Lines
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21340%2F19%3A00332744" target="_blank" >RIV/68407700:21340/19:00332744 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.1016/j.jmir.2019.03.125" target="_blank" >http://dx.doi.org/10.1016/j.jmir.2019.03.125</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.jmir.2019.03.125" target="_blank" >10.1016/j.jmir.2019.03.125</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Preliminary In-vitro Study of 223Ra Impact on Selected Tissue and Tumor Cell Lines
Popis výsledku v původním jazyce
Targeted alpha-particle therapy (TAT) is very rapidly evolving field of radionuclide therapy. Nevertheless, there are some severe issues that need to be addressed to enable TAT to be a leading modality in radionuclide therapy. The nuclear recoil effect that causes the daughter nuclei release from the original radiopharmaceuticals is critical for alpha emitters. Moreover, targeting and proper dosimetry is still an issue. Therefore, it is very important to understand the dosimetry both on cellular and subcellular level. The first step of each dosimetric study is the determination of survival curves. For our preliminary study we used Ra-223 as a model alpha-emitting nuclide. Selected cell lines were V79 (Chinese hamster lung fibroblasts), DU145 (human adenocarcinoma cell line) and U87 (human primary glioblastoma cell line) obtained from American Type Culture Collection (ATCC). All obtained survival curves correspond to the linearly quadratic model. Sensitivity of both human carcinoma cell lines (adenocarcinoma and glioblastoma cell line) to Ra-223 treatment is higher than the sensitivity of Chinese hamster cell line. Preliminary results indicates higher radiosensitivity of DU145 and U87 against V79 cells. The achieved results enabled further progress in enhancing the dosimetric knowledge.
Název v anglickém jazyce
Preliminary In-vitro Study of 223Ra Impact on Selected Tissue and Tumor Cell Lines
Popis výsledku anglicky
Targeted alpha-particle therapy (TAT) is very rapidly evolving field of radionuclide therapy. Nevertheless, there are some severe issues that need to be addressed to enable TAT to be a leading modality in radionuclide therapy. The nuclear recoil effect that causes the daughter nuclei release from the original radiopharmaceuticals is critical for alpha emitters. Moreover, targeting and proper dosimetry is still an issue. Therefore, it is very important to understand the dosimetry both on cellular and subcellular level. The first step of each dosimetric study is the determination of survival curves. For our preliminary study we used Ra-223 as a model alpha-emitting nuclide. Selected cell lines were V79 (Chinese hamster lung fibroblasts), DU145 (human adenocarcinoma cell line) and U87 (human primary glioblastoma cell line) obtained from American Type Culture Collection (ATCC). All obtained survival curves correspond to the linearly quadratic model. Sensitivity of both human carcinoma cell lines (adenocarcinoma and glioblastoma cell line) to Ra-223 treatment is higher than the sensitivity of Chinese hamster cell line. Preliminary results indicates higher radiosensitivity of DU145 and U87 against V79 cells. The achieved results enabled further progress in enhancing the dosimetric knowledge.
Klasifikace
Druh
O - Ostatní výsledky
CEP obor
—
OECD FORD obor
10402 - Inorganic and nuclear chemistry
Návaznosti výsledku
Projekt
Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2019
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů